Staidson Beijing Biopharma Net Asset Quality Index
Staidson Beijing Biopharma net asset quality index. Staidson Beijing Biopharma (300204) has a Net Asset Quality Index of 62.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.28 Billion minus total liabilities of CN¥486.07 Million yields net assets of CN¥794.92 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Staidson Beijing Biopharma earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Staidson Beijing Biopharma (2007–2025)
Net asset quality index of Staidson Beijing Biopharma from 2007 to 2025. This chart shows how Staidson Beijing Biopharma's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 62.1%, representing net assets of CN¥794.92 Million against total assets of CN¥1.28 Billion CNY. See 300204 book value for net asset value and shareholders' equity analysis.
Staidson Beijing Biopharma Net Asset Quality Index by Year (2007–2025)
Staidson Beijing Biopharma net asset quality index by year from 2007 to 2025. The table below presents the year-by-year Net Asset Quality Index for Staidson Beijing Biopharma from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300204 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 63.7% | CN¥806.72 Million | CN¥1.27 Billion | CN¥459.48 Million | ▼ -16.0 pp |
| 2024 | 79.7% | CN¥916.76 Million | CN¥1.15 Billion | CN¥232.85 Million | ▲ +3.1 pp |
| 2023 | 76.6% | CN¥1.02 Billion | CN¥1.33 Billion | CN¥311.55 Million | ▼ -4.5 pp |
| 2022 | 81.1% | CN¥1.35 Billion | CN¥1.67 Billion | CN¥315.45 Million | ▼ -3.8 pp |
| 2021 | 84.9% | CN¥1.55 Billion | CN¥1.83 Billion | CN¥276.25 Million | ▼ -0.6 pp |
| 2020 | 85.5% | CN¥1.59 Billion | CN¥1.86 Billion | CN¥268.70 Million | ▼ -2.3 pp |
| 2019 | 87.8% | CN¥1.64 Billion | CN¥1.86 Billion | CN¥227.18 Million | ▼ -0.9 pp |
| 2018 | 88.7% | CN¥2.46 Billion | CN¥2.77 Billion | CN¥314.30 Million | ▲ +4.6 pp |
| 2017 | 84.1% | CN¥2.21 Billion | CN¥2.63 Billion | CN¥419.14 Million | ▲ +2.4 pp |
| 2016 | 81.6% | CN¥1.92 Billion | CN¥2.35 Billion | CN¥432.32 Million | ▲ +0.3 pp |
| 2015 | 81.3% | CN¥1.68 Billion | CN¥2.07 Billion | CN¥387.06 Million | ▼ -2.3 pp |
| 2014 | 83.6% | CN¥1.51 Billion | CN¥1.81 Billion | CN¥297.54 Million | ▼ -0.1 pp |
| 2013 | 83.7% | CN¥1.31 Billion | CN¥1.57 Billion | CN¥255.47 Million | ▼ -2.9 pp |
| 2012 | 86.6% | CN¥1.24 Billion | CN¥1.43 Billion | CN¥192.15 Million | ▼ -9.3 pp |
| 2011 | 95.9% | CN¥1.10 Billion | CN¥1.15 Billion | CN¥47.32 Million | ▲ +33.1 pp |
| 2010 | 62.8% | CN¥166.23 Million | CN¥264.88 Million | CN¥98.66 Million | ▼ -17.7 pp |
| 2009 | 80.5% | CN¥119.72 Million | CN¥148.75 Million | CN¥29.03 Million | ▲ +12.3 pp |
| 2008 | 68.2% | CN¥62.82 Million | CN¥92.07 Million | CN¥29.25 Million | ▲ +27.0 pp |
| 2007 | 41.2% | CN¥33.87 Million | CN¥82.22 Million | CN¥48.35 Million | — |